Exchange: NASDAQ·Updated 07:36 PM EDT

QTTB News

News
all
press releases
Q32 Bio to Participate in Upcoming September Investor Conferences
Q32 Bio to Participate in Upcoming September Investor Conferences Q32 Bio to Participate in Upcoming September Investor Conferences PR Newswire WALTHAM, Mass., Sept. 1, 2026 WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company...
PR Newswire
More News
Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Aug. 5, 2026 -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical...
PR Newswire
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet
The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice
Does Q32 Bio (QTTB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Why Is Q32 Bio Stock Falling Wednesday?
Q32 Bio (QTTB) stock slips after pricing a $200M public offering at $18.25. Get the details on the deal and share reaction.read more...
Benzinga
Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
The consensus price target hints at an 80.1% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants PR Newswire WALTHAM, Mass., July 14, 2026 WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc...
PR Newswire
$100 Invested In Q32 Bio 5 Years Ago Would Be Worth This Much Today
Q32 Bio (NASDAQ:QTTB) has outperformed the market over the past 5 years by 11.82% on an annualized basis producing an average annual return of 23.91%. Currently, Q32 Bio has a market capitalization of $317.42 million.read more...
Benzinga
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures mixed, Nasdaq 100 up 100 pts. Telefonaktiebolaget LM Ericsson falls 9.2% in pre-market. Other stocks moving lower in pre-market.read more...
Benzinga

Advertisement|Remove ads.